Validated Assessment Tools for Mephentermine Addiction Severity
Use the DSM-5 criteria for stimulant use disorder to evaluate mephentermine addiction severity, supplemented by structured instruments like the Addiction Severity Index (ASI) or Drug Abuse Screening Test-10 (DAST-10) to quantify functional impairment across multiple domains. 1, 2
Primary Diagnostic Framework
The DSM-5 provides the foundational approach for assessing stimulant use disorder severity, which directly applies to mephentermine (a sympathomimetic amine structurally similar to amphetamines) 2, 3. The severity is determined by the number of criteria met:
- Mild: 2-3 criteria
- Moderate: 4-5 criteria
- Severe: 6 or more criteria
Key criteria to assess include 2:
- Craving or strong desire to use
- Inability to cut down or control use
- Continued use despite physical/psychological problems
- Tolerance (needing increased doses for effect)
- Withdrawal symptoms when stopping
- Failure to fulfill major responsibilities
- Social/interpersonal problems due to use
- Hazardous use patterns
Structured Assessment Instruments
Drug Abuse Screening Test-10 (DAST-10)
This is a brief, validated self-report tool that accurately identifies substance abuse and dependence 4. Scoring:
- 0 points = low risk
- 1-3 points = moderate risk (monitor and reassess)
3 points = substance abuse or dependence
The DAST-10 has sensitivity of 90-100% and specificity of 77% for detecting substance use disorders 4.
Addiction Severity Index (ASI)
The ASI is a multidimensional interview-based assessment that evaluates problem severity across seven domains 5, 6:
- Medical status
- Employment/support
- Drug use
- Alcohol use
- Legal status
- Family/social relationships
- Psychiatric status
The ASI composite scores provide quantifiable measures of functional impairment, though it shows ceiling effects in some domains 6.
Addiction Severity Assessment Tool (ASAT)
This is a 27-item self-report measure specifically designed for substance abuse treatment clients, assessing 5:
- Daily functioning impairment
- Relational functioning
- Dysphoric states
- Dependence severity
- Recovery self-efficacy
- Existential factors
The ASAT demonstrates good reliability and validity, with sensitivity to treatment changes over time 5.
Specific Considerations for Mephentermine
Dosage and Pattern Assessment
Document the following quantitative parameters 3, 7, 8:
- Daily dosage: Median reported use is 300 mg/day (range 183.8-412.5 mg), though therapeutic doses are much lower
- Route of administration: Intravenous use is most common (77.8% of cases), indicating higher addiction severity
- Frequency of injections: Multiple daily injections suggest compulsive use patterns
- Duration of use: Chronic use indicates established dependence
- Procurement patterns: Obtaining from non-medical sources (chemists, gym trainers) indicates problematic use
Functional Impairment Markers
Assess these specific domains 7, 8:
- Occupational: Performance enhancement motivation (63% of users), employment status
- Psychiatric complications: Psychotic symptoms during intoxication (43-67% of users), anxiety, insomnia
- Physical health: Cardiovascular symptoms, injection site complications
- Social consequences: Relationship problems, legal issues
- Co-occurring substance use: 40% report polysubstance use (alcohol, tobacco, anabolic steroids)
Objective Measures Beyond Self-Report
Attention Bias Testing
Attention bias to drug-related cues correlates more reliably with addiction severity than subjective craving reports 9. This is particularly relevant when patients underreport use due to social desirability or legal concerns. The attention bias test measures reaction time delays when exposed to drug-related versus neutral stimuli, providing an objective marker of addiction severity 9.
Urine Toxicology
Confirmatory urine testing validates self-reported use patterns and detects polysubstance use 7. However, routine urine testing should supplement, not replace, clinical assessment 4.
Clinical Pitfalls to Avoid
Don't rely solely on subjective craving scores: Self-reported craving may be influenced by social approval, legal concerns, or self-masking, particularly in compulsory treatment settings 9
Screen for psychotic symptoms: 43-67% of mephentermine users experience psychosis during intoxication, which may not be volunteered 7, 8
Assess for performance enhancement context: Most users (63%) initiate mephentermine for athletic or occupational performance, not recreational euphoria 7, 8
Evaluate cardiovascular risk: Mephentermine's sympathomimetic effects pose significant cardiovascular risks that require medical assessment 10
Consider the "diagnostic orphan" problem: Patients with 2 dependence criteria but no abuse criteria may have clinically significant problems despite not meeting full diagnostic thresholds 2
Practical Implementation Algorithm
- Initial screening: Use DAST-10 for rapid identification (sensitivity 90-100%)
- Diagnostic confirmation: Apply DSM-5 stimulant use disorder criteria to determine severity (mild/moderate/severe)
- Comprehensive assessment: Administer ASI or ASAT to quantify functional impairment across domains
- Objective validation: Consider attention bias testing if self-report appears unreliable; confirm with urine toxicology
- Specific mephentermine parameters: Document daily dosage, injection frequency, route, procurement sources, and performance enhancement context
- Comorbidity screening: Assess for psychotic symptoms, anxiety, depression, and co-occurring substance use (present in 40-60% of cases)
The evidence base for mephentermine-specific assessment tools is limited, as this is an emerging pattern of misuse primarily reported from India 7, 8. However, the validated instruments for stimulant use disorders provide a robust framework that can be adapted to this specific substance.